Anthropic outlines six drug-development partnerships and in-house Mithril work

Anthropic’s October 27 life‑sciences update describes two organizational tracks: research with outside partners and programs it is running itself. The company names six external partners: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. It says those relationships developed over the preceding several months; the post is not an announcement that all six agreements were signed on October 27.

Anthropic presents the collaborations as a way to encounter different tasks and bottlenecks within real drug‑development programs, and to learn where Claude needs improvement. That is broader than offering software for one research task. It also makes the partners’ involvement distinct from a generally available product or a promise that any organization can enter the same collaboration.

The same update says Anthropic has acquired Mithril Medicine and that founder Cody Tranbarger is continuing his research at Anthropic, with plans to start additional programs. The post does not specify when the acquisition closed. Its publication date should not be used as the deal’s closing date.

Anthropic describes Claude’s role at Mithril as including contracts, logistics and coordination of experiments with outside laboratories, alongside other operational work. That detail matters to the scope of the announcement: using AI in a research organization can involve organizing the work around a program, rather than only proposing scientific ideas.

The external partnerships and Mithril are therefore different forms of involvement. One track places Anthropic alongside other organizations’ programs; the other brings a program and its founder into Anthropic. Neither organizational arrangement, by itself, establishes that a medicine works.

Anthropic [describes the research as early and mostly preclinical](https://www.anthropic.com/research/early‑progress‑drug‑development)—for the most part, not yet at the stage where the drugs are being tested in humans. The company’s account of its work should not be read as an approved treatment, a demonstrated clinical benefit or a commitment that a particular program will succeed. The post also points to existing researcher‑access efforts, including its guest‑investigator call. Researchers seeking an application route can consult OpenTools’ [separate explanation of the guest program’s application and data requirements](https://opentools.ai/news/anthropic‑life‑sciences‑guest‑investigator‑program‑applications‑data). That is a different reader task from understanding the partner and in‑house program structure described here. The substantive change in this update is the view it provides of how Anthropic is participating in drug‑development work. This article addresses that organizational scope; it does not independently assess the linked technical reports, biological findings or clinical prospects. Anthropic co‑founder and CEO Dario Amodei at TechCrunch Disrupt in San Francisco on September 20, 2023, as identified by the photographer. Archive company context, not a Mithril acquisition event, partner research activity, experiment or evidence of a medical result. Photo: [Kimberly White/Getty Images for TechCrunch](https://www.flickr.com/photos/techcrunch), ©2023 Getty Images; [TechCrunch, via Wikimedia Commons](https://commons.wikimedia.org/wiki/File:Dario_Amodei_at_TechCrunch_Disrupt_2023_04.jpg), [CC BY 2.0](https://creativecommons.org/licenses/by/2.0/). Original retained unchanged; display crops and resizes it.